Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
Precision BioSciences, Inc. (DTIL)
Last precision biosciences, inc. earnings: 11/12 07:15 am
Check Earnings Report
Company Research
Source: Business Wire
– PBGENE-HBV preclinical data reinforce safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study –– Phase 1 dose escalation and expansion trial, ELIMINATE-B, designed to assess safety and efficacy measured by durable reduction of key viral biomarkers –– Global study recruiting patients following clearance of first clinical trial application (CTA), with additional CTAs pending approval; U.S. investigational new drug (IND) anticipated in 2025 –– Investor event today, November 15, 10:00 a.m. EST / 7:00 a.m. PST, to feature presentations from company management and key opinion leader perspectives on PBGENE-HBV – DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today will present preclinical data supporting the advancement
Show less
Read more
Impact Snapshot
Event Time:
DTIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DTIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DTIL alerts
High impacting Precision BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
DTIL
News
- Precision BioSciences to Participate in Upcoming November Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Precision BioSciences to Participate in Upcoming November Investor ConferencesBusiness Wire
- Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B [Yahoo! Finance]Yahoo! Finance
- Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Precision BioSciences GAAP EPS of -$2.25, revenue of $0.6M [Seeking Alpha]Seeking Alpha
DTIL
Earnings
- 11/4/24 - Miss
DTIL
Sec Filings
- 11/21/24 - Form 4
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- DTIL's page on the SEC website